Chalfont, PA (PRWEB) October 17, 2012
Genomind, LLC, a neuropsychiatric personalized medicine company, is proud to announce that General Manager Nancy Grden will be speaking today at the 2012 OPEN MINDS Technology & Informatics Institute conference in Baltimore as part of a panel presentation.
The session titled “Genetics, Neurotech & Personalized Medicine: Using Emerging Science to Improve Treatment of Cognitive Disorders,” will discuss the advancements in personalized medicine and how this changing facet of the health care industry will affect how patients and medical professionals approach diagnosis and treatment in the future. Grden will share the recent success Genomind has made with the company’s Genecept™ Assay, which analyzes patient saliva for biomarkers and genes that may have impact on treatments for psychiatric disorders. She will also weigh in on the implications of such advancements on service providers, and future breakthroughs that may be on the horizon. The session will take place at 9:30 am.
Grden is an experienced executive in numerous industries, and was instrumental in Genomind’s formation and launch. As general manager she is responsible for all aspects of Genomind’s development, commercialization, and future strategy.
OPEN MINDS Technology & Informatics Institute (ww.openminds.com/tii) will run October 17-18 at the Baltimore Convention Center. It is the only event of its kind that focuses on the latest advancements in technology and informatics for the health care field and how they will impact the public.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/products/assay.